idecabtagene vicleucel,luspatercept,liso-cel,nivolumab
2seventy bio,bms
['abecma', 'reblozyl', 'opdivo', 'breyanzi', 'bms']
bms #oncology #portfolio grew a &gt;30% cagr in the last 5 years, future growth is driven by #immunotherapy product opdivo and reblozyl, breyanzi, abecma. excited for #whatsnext @ #esmo22 follow us for more 
A healthcare-focused strategy consulting firm, providing bench-to-bedside decision support to pharmaceutical, biotech, and medical device companies